| 1 |
33279389 | Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). | 2021 Mar |
1 |
| 2 |
33432890 | A network meta-analysis of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and diabetes mellitus. | 2021 Nov |
1 |
| 3 |
33509171 | Cost-effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China. | 2021 Jan 28 |
1 |
| 4 |
33690135 | Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study. | 2021 Mar |
1 |
| 5 |
34068569 | Could DOAC Be a Better Choice Than Warfarin in Low Compliance Patients with Fontan Procedure? | 2021 May 10 |
1 |
| 6 |
34321399 | Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study. | 2021 Nov 1 |
2 |
| 7 |
32871929 | The resolution of carotid arterial thrombus by oral anticoagulation after IV thrombolysis for chemotherapy-induced stroke: A case report. | 2020 Aug 28 |
1 |
| 8 |
33224741 | Association between platelet count and the risk of bleeding among patients with nonvalvular atrial fibrillation taking dabigatran after radiofrequency ablation: a cohort study. | 2020 Oct |
1 |
| 9 |
31490268 | Peripheral leukocyte count and risk of bleeding in patients with non-valvular atrial fibrillation taking dabigatran: a real-world study. | 2019 Sep 20 |
1 |
| 10 |
29653649 | Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry. | 2018 Apr |
2 |
| 11 |
29695165 | Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. | 2018 Sep |
2 |
| 12 |
28003013 | Oral Antiplatelet and Anticoagulant Agents in the Prevention and Management of Ischemic Stroke. | 2017 |
1 |
| 13 |
28500254 | Increased Thromboembolic Events With Dabigatran Compared With Vitamin K Antagonism in Left Ventricular Assist Device Patients: A Randomized Controlled Pilot Trial. | 2017 May |
1 |
| 14 |
28857611 | Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. | 2017 Nov |
1 |
| 15 |
27709460 | A Prospective, Randomized, Open-Label Study to Evaluate Two Management Strategies for Gastrointestinal Symptoms in Patients Newly on Treatment with Dabigatran. | 2016 Dec |
2 |
| 16 |
27716554 | Efficacy and safety of novel anticoagulants versus vitamin K antagonists in patients with mild and moderate to severe renal insufficiency: Focus on apixaban. | 2016 Dec 15 |
1 |
| 17 |
25739533 | Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. | 2015 Jun |
1 |
| 18 |
26152604 | Low dose dabigatran versus uninterrupted acenocoumarol for peri-procedural anticoagulation in atrial fibrillation catheter ablation. | 2015 Sep-Oct |
1 |
| 19 |
26508666 | Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation. | 2015 Nov |
1 |
| 20 |
24499559 | Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. | 2014 Feb 5 |
1 |
| 21 |
24577485 | Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. | 2014 May 5 |
3 |
| 22 |
24711238 | [New direct oral oral anticoagulants (DOACs) - indications of DOACs]. | 2014 Mar |
1 |
| 23 |
24880227 | Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. | 2014 Sep |
1 |
| 24 |
24911432 | Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria. | 2014 |
3 |
| 25 |
25193361 | Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. | 2014 Dec |
1 |
| 26 |
22782539 | Pharmacokinetic and pharmacodynamic effects of comedication of clopidogrel and dabigatran etexilate in healthy male volunteers. | 2013 Mar |
1 |
| 27 |
22843168 | The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis. | 2013 Jan |
1 |
| 28 |
23182947 | A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients. | 2013 Jan 22 |
1 |
| 29 |
23271794 | Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. | 2013 Feb 5 |
4 |
| 30 |
23474679 | Reversing dabigatran in life-threatening bleeding occurring during cardiac ablation with factor eight inhibitor bypassing activity. | 2013 May |
1 |
| 31 |
24204920 | New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. | 2013 |
1 |
| 32 |
24291856 | [Evidence of novel oral anticoagulants (NOAC)]. | 2013 |
1 |
| 33 |
22186961 | Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. | 2012 Mar |
2 |
| 34 |
22215856 | Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. | 2012 Feb 7 |
1 |
| 35 |
22367842 | Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic. | 2012 Mar |
2 |
| 36 |
22504514 | Fatal basilar artery occlusion under dabigatran occurring 13 days after femoral embolectomy. | 2012 May |
1 |
| 37 |
22575324 | Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. | 2012 Aug 21 |
3 |
| 38 |
22739760 | Dabigatran for stroke prevention in atrial fibrillation. | 2012 |
3 |
| 39 |
22801398 | Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. | 2012 Aug |
3 |
| 40 |
21717198 | Dabigatran in atrial fibrillation: pharmacology and clinical trials. | 2011 Dec |
2 |
| 41 |
20967400 | Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. | 2010 Dec |
2 |
| 42 |
19376304 | Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. | 2009 May |
1 |